Design and Analysis of Clinical Trials for Predictive Medicine

Design and Analysis of Clinical Trials for Predictive Medicine provides statistical guidance on conducting clinical trials for predictive medicine. It covers statistical topics relevant to the main clinical research phases for developing molecular diagnostics and therapeutics—from identifying molecular biomarkers using DNA microarrays to confirming their clinical utility in randomized clinical trials. The foundation of modern clinical trials was laid many years before modern developments in biotechnology and genomics. Drug development in many diseases is now shifting to molecularly targeted treatment. Confronted with such a major break in the evolution toward personalized or predictive medicine, the methodologies for design and analysis of clinical trials is now evolving. This book is one of the first attempts to contribute to this evolution by laying a foundation for the use of appropriate statistical designs and methods in future clinical trials for predictive medicine. It is a useful resource for clinical biostatisticians, researchers focusing on predictive medicine, clinical investigators, translational scientists, and graduate biostatistics students.

INTRODUCTORY OVERVIEWClinical Trials for Predictive Medicine: New Paradigms and ChallengesRichard Simon, Shigeyuki Matsui, and Marc BuyseAn Industry Statistician’s Perspective on Personalized Health Care Drug DevelopmentJane Fridlyand, Ru-Fang Yeh, Howard Mackey, Thomas Bengtsson, Paul Delmar, Greg Spaniolo, and Grazyna LiebermanAnalytical Validation of In Vitro Diagnostic TestsRobert Becker, Jr.EARLY CLINICAL TRIALS USING BIOMARKERSPhase I Dose-Finding Designs and Their Applicability to Targeted TherapiesTakashi Daimon, Akihiro Hirakawa, and Shigeyuki MatsuiAn Overview of Phase II Clinical Trial Designs with BiomarkersLisa McShane and Sally HunsbergerBayesian Adaptive Methods for Clinical Trials of Targeted AgentsPeter ThallOutcome-Adaptive Randomization in Early Clinical TrialsEdward Korn and Boris FreidlinChallenges of Using Predictive Biomarkers in Clinical TrialsSumithra Mandrekar and Daniel SargentPHASE III RANDOMIZED CLINICAL TRIALS USING BIOMARKERSComparison of Randomized Clinical Trial Designs for Targeted AgentsAntje Hoering, Mike LeBlanc, and John CrowleyPhase III All-Comers Clinical Trials with a Predictive BiomarkerShigeyuki Matsui, Yuki Choai, and Takahiro NonakaEvaluation of Clinical Utility and Validation of Gene Signatures in Clinical TrialsStefan Michiels and Federico RotoloANALYSIS OF HIGH-DIMENSIONAL DATA AND GENOMIC SIGNATURE DEVELOPMENTSStatistical Issues in Clinical Development and Validation of Genomic SignaturesShigeyuki MatsuiUnivariate Analysis for Gene Screening: Beyond Multiple TestingHisashi Noma and Shigeyuki MatsuiStatistical and Machine-Learning Methods for Class Prediction in High DimensionOsamu Komori and Shinto EguchiSurvival Risk Prediction Using High-Dimensional Molecular DataHarald Binder, Thomas Gerds, and Martin SchumacherRANDOMIZED TRIALS WITH BIOMARKER DEVELOPMENT AND VALIDATIONAdaptive Clinical Trial Designs with Biomarker Development and ValidationBoris Freidlin and Richard SimonDevelopment and Validation of Continuous Genomic Signatures in Randomized Clinical TrialsShigeyuki MatsuiEVALUATION OF SURROGATE BIOMARKERSBiomarker-Based Surrogate EndpointsMarc Buyse, Tomasz Burzykowski, Geert Molenberghs, and Ariel Alonso

Shigeyuki Matsui is a professor in the Department of Biostatistics at Nagoya University Graduate School of Medicine in Japan. He is also a visiting professor at the Institute of Statistical Mathematics. Dr. Matsui has served as council and nominating committee member of the International Biometric Society. He is currently council of the Biometric Society of Japan (BSJ) and editor-in-chief of the Japanese Journal of Biometrics. He is the recipient of the 2014 Award from the BSJ. Dr. Matsui is also a frequent reviewer commissioned by government and advisor to pharmaceutical companies in Japan. He holds degrees in engineering from the Tokyo University of Science in Japan. Marc E. Buyse is the founder of the International Drug Development Institute in Louvain-la-Neuve, Belgium and of CluePoints Inc. in Cambridge, Massachusetts. He is also an associate professor of biostatistics at Hasselt University in Belgium. He was president of the International Society for Clinical Biostatistics, president of the Quetelet Society, and fellow of the Society for Clinical Trials. He worked at the European Organization for Research and Treatment of Cancer in Brussels and at the Dana Farber Cancer Institute in Boston. He holds degrees in engineering and statistics from Brussels University, management from the Cranfield School of Management in the UK, and a doctorate in biostatistics from Harvard University. Richard M. Simon is chief of the Biometric Research Branch at the National Cancer Institute in Bethesda, Maryland. He leads a multidisciplinary group of scientists developing and applying methods for the application of genomics to cancer therapeutics. Dr. Simon is the architect of BRB-ArrayTools software used for the analysis of microarray and digital expression, copy number, and methylation data. He is the recipient of the 2013 Karl E. Peace Award for Outstanding Statistical Contributions for the Betterment of Society and is the author or coauthor of more than 450 publications.